References | CAYSTON® (aztreonam for inhalation solution)

  1. Pseudomonas. Cystic Fibrosis Foundation website. Accessed January 13, 2017.
  2. Cunningham JC, Taussig LM. Respiratory System. In: An Introduction to Cystic Fibrosis: For Patients and Their Families. 6th ed. Cystic Fibrosis Foundation; 2013:41-58.
  3. Cystic Fibrosis. US National Library of Medicine website. Updated January 24, 2017. Accessed January 29, 2017.
  4. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680-689.
  5. Pritt B, O'Brien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128:32-34.
  6. Cystic Fibrosis Foundation Patient Registry. 2016 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation; 2017. Accessed October 8, 2018.
  7. Basics of lung care. Cystic Fibrosis Foundation website. Accessed October 20, 2015.
  8. Cystic fibrosis. National Heart, Lung, and Blood Institute website. Accessed October 20, 2015.
  9. Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest. 2009;135:1223-1232.
  10. Data on file, Gilead Sciences, Inc.